Biotech startup looks to turn founders' experience, $20 million against epilepsy
San Francisco's Montara Therapeutics secures $20 million in seed funding to advance epilepsy drug development and explore ...
Fierce Biotech5h
‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Mass. man gets prison time for defrauding Takeda Pharmaceutical Co. of $2.3M
A Massachusetts man who, along with his girlfriend, defrauded Takeda Pharmaceutical Co. of $2.3 million and used the money to ...
American Association of Individual Investors3d
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Veracyte, Inc. Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...
ABC63d
Brockton man sentenced for spending defrauded money on Mercedes, Boston Seaport condo
A Brockton man was sentenced for defrauding a pharmaceutical company out of $2.3 million and spending the proceeds on a ...
Healio4d
‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
Fierce Pharma6d
Fierce Pharma Asia—Trump's investment policy; Pfizer's tariff mitigation plan; CMIC's stake sale
U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...
Medical Marketing & Media6d
Rx Rundown: AbbVie, Jazz Pharmaceuticals, Sofinnova Partners and more
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...